Acer Therapeutics — Investor Presentation (May 2020)
44 slides from Acer Therapeutics's investor presentation, May 11, 2020
Slide 1: Corporate Presentation May 2020
Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Significant Unmet Medical Needs Corporate Presentation May 2020 Nasdaq: ACER Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Corporate Overview
Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs Headquartered: Newton, MA Headcount: 18 Founded: December 2013 Public: September 2017 Cash
Slide 4: Executive Leadership Team
Executive Leadership Team Chris Schelling CEO & Founder 20 years; strategic commercial development & orphan Will Andrews, MD Chief Medical Officer 20 years; clinical development, medical affairs & orphan M.D. Yale University School of Medicine Harry Palmin Chief Operating & Financial Officer 25 year
Slide 5: Investment Highlights
Investment Highlights Acer’s pipeline includes four clinical-stage product candidates: Emetine for the treatment of COVID-19 EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a taste-masked, imm
Slide 6: Clinical Pipeline
Program / Indication Novel MOA / Unique Characteristics Development Status Emetine Hydrochloride COVID-19 Unique MOA; restores cellular stress response Phase 2/3* EDSIVOTM (celiprolol) vascular Ehlers-Danlos syndrome (COL3A1+) Induces vascular dilatation and smooth muscle relaxation TBD** ACER-001 (
Slide 7: Emetine: antiviral activity through cellular stress response
Potent antiviral activity through modulation of cellular stress response Restores cellular stress response, inhibiting viral replication Believed to be the only drug in development exploiting this MOA Mechanism of Action Global pandemic with no currently approved therapeutic options for COVID-19 out
Slide 8: Emetine background and history
Emetine is one of the main alkaloids found in ipecacuanha (ipecac) root Clinically, emetine hydrochloride was originally marketed in the U.S. as a topical anti-infective in dental applications (ca 1890s by Eli Lilly and Company) Later, emetine hydrochloride for injection gained market adoption as a
Slide 9: Emetine: Broad & Potent Antiviral Activity
Clinically, emetine has been used to treat approximately 700 patients (including pediatrics) with viral hepatitis1 and varicella-zoster virus2 The antiviral activity of emetine in various in vitro/in vivo models is provided below: Emetine Emetine: Broad & Potent Antiviral Activity Virus Type Antivir
Slide 10: Emetine: Uniquely Suited for COVID-19
Emetine Emetine: Uniquely Suited for COVID-19 1 https://www.researchsquare.com/article/rs-17218/v1 2 https://doi.org/10.1016/j.antiviral.2020.104786 3 Asano et al. European Journal of Drug Metabolism and Pharmacokinetics volume 27, pages17–27(2002) 4 Del Puerto et al. Pren. méd. argent., 55: 818, 1
Slide 11: Emetine: Unique Mechanism of Action
Emetine Emetine: Unique Mechanism of Action In high-density infected cells (A) emetine induces (1) nuclear translocation of RPS14 (2) followed by RPS14 binding to MDM2 (3 & 4) resulting in disruption of the interaction between MDM2-p53 (6) and MDM2- viral IE2 (5 & 7), and by RPS14 ubiquitination and
Slide 12: Emetine: Safety
Patients treated with 1 mg/kg/day emetine daily via SC injection for 10 days (cumulative dose 650 mg) did not experience any notable toxicity1 Electrocardiographic abnormalities are seen, but not often associated with significant cardiac symptoms2,3,4 T wave inversion (TWI) is the first to appear an
Slide 13: Emetine: Proposed Clinical Trial
Emetine Emetine: Proposed Clinical Trial* Title: A Phase 2/3 Randomized, Blinded, Placebo-Controlled Clinical Study to Evaluate the Safety and Activity of Emetine Hydrochloride Injection, USP (ACER-2820) in High Risk, Symptomatic Adults with Confirmed SARS-CoV-2 Infection Not Requiring Hospitalizati
Slide 14: Emetine: Regulatory Path
Emetine Emetine: Regulatory Path Acer submitted Pre-Investigational New Drug (Type B) expedited (PIND 149290) briefing package on April 14, 2020 Initial written responses received from Division of Antivirals (DAV) on April 29, 2020 – requested additional PIND information: Systematic Literature Datab
Slide 15: EDSIVO mechanism and disease overview
EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO’s™ potential beneficial effects in vEDS thought to be through vascular dilatation and smooth muscle relaxa
Slide 16: EDSIVO: Regulatory Timeline
June 2019: Received CRL from FDA CRL stated it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS December 2019: Submitted Formal Dispute Resolution Request (FDRR) to the Office of New Drugs (ON
Slide 17: FDA: Substantial Evidence of Effectiveness
EDSIVO™ FDA: Substantial Evidence of Effectiveness Two adequate and well-controlled clinical investigations2 One adequate and well-controlled investigation plus confirmatory evidence2 One adequate and well-controlled investigation1 THE QUANTITY OF CLINICAL EVIDENCE TO ESTABLISH EFFECTIVENESS In many
Slide 18: Vascular Ehlers-Danlos Syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Hollow Organs (e.g. gastrointestinal, uterine) Autosomal dominant (50%); spontaneous mutations (50%) Diagnos
Slide 19: EDSIVO Unique Mechanism of Action
Cardiology in Review 2017;25: 247–253 *Hypertension 2003 Nov;42(5):1004-13 EDSIVO™ has a unique pharmacological profile: β2 and β3 adrenergic receptor agonist Selective β1 and ⍺2 adrenergic receptor antagonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Activates en
Slide 20: EDSIVO BBEST Trial: COL3A1+ Subpopulation
Efficacy: 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ pat
Slide 21: ACER-001 overview
Small molecule with unique MOAs in various disorders UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCDs: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCDs: Currently treated with RAVICTI®, BUPHENYL®, AMMON
Slide 22: UCDs: Clinical Manifestations
Newborns with severe urea cycle disorders become catastrophically ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a
Slide 23: UCDs: Unmet Need
ACER-001 UCDs: Unmet Need BUPHENYL®: Foul odor and foul/bitter taste; considered unpalatable* 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients were prescribed less than target dose due to tolerability Only 25% of patients indicated that th
Slide 24: ACER-001: Differentiation
Phenylbutyrate Formulations ACER-001* RAVICTI® BUPHENYL® Efficacy / Safety in UCDs ✓ ✓ ✓ Palatability / Compliance ✓ ✓ ✘ ** Pricing (Per Patient Per Year) TBD, likely near BUPHENYL $158k-$1.2M*** $204k-$402k*** Formulation Multi-Particulate (Sachet) Oil (Tablespoons) Powder/Tablets (up to 40 tablets
Slide 25: ACER-001 bioavailability and bioequivalence trials
Bioavailability and bioequivalence (BE) trials: Part A: single-center, single-blind, randomized, single-dose crossover study designed to evaluate bioavailability of three different oral suspension formulations of ACER-001 compared to BUPHENYL® in 20 healthy adult subjects Successfully completed and
Slide 26: UCDs: Bioequivalence Trial Results (Part A)
ACER-001 UCDs: Bioequivalence Trial Results (Part A) PBA = phenylbutyrate; PAA = phenylacetate PK Plasma Concentration (PBA) ACER-001 Buphenyl -100 -50 0 50 100 150 200 250 300 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 PK Plasma Concentration (PAA) Lab Name Parameter Geometric Mean Difference Lower 90%
Slide 27: UCDs: Market Opportunity
Target existing Rx market share in UCDs Currently 1,100 patients diagnosed with ~600 patients on Rx therapy* 2018 U.S. revenue for Ravicti® & Buphenyl® = $248.4M Goal: transition patients from Ravicti® & Buphenyl® to ACER-001 and capture a portion of new UCDs Rx “Transition” Value Story: A cost-effe
Slide 28: ACER-001: Exclusivity / IP
ACER-001 ACER-001: Exclusivity / IP Filed formulation patent application (filed Oct. 2016) Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532] in MSUD Exclusive license rights from Baylor College of Medicine UCDs: 505(b)(2) application
Slide 29: Osanetant overview
Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus iVMS: Induced Vasomotor Symptoms where Hormone Replacement Therapy (HRT) is likely contrain
Slide 30: Osanetant History
Acer acquired worldwide rights to osanetant from Sanofi in December 2018 Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 21 completed Phase 1 and
Slide 31: Vasomotor Symptoms (VMS): Overview
VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) While VMS associated with menopause can often be treated with hormone replacement therapy (HRT), there are patients who experience VMS who
Slide 32: Induced Vasomotor Symptoms (iVMS)
Osanetant Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 y
Slide 33: iVMS: The Unmet Need
Osanetant iVMS: The Unmet Need Induced vasomotor symptoms (iVMS) are well documented with the use of hormonal cancer therapies and certain surgical procedures Symptoms such as hot flashes can appear immediately and be severe Traditional HRTs are usually contraindicated Non-adherence to therapy can b
Slide 34: NK3 Receptor (Neurokinin B)
Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d
Slide 35: NK3R Antagonist Clinical POC in VMS (fezolinetant)
Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Hot Flash Frequency Reported a
Slide 36: NK3R Antagonist Clinical POC in VMS (pavinetant)
Osanetant NK3R Antagonist Clinical POC in VMS Prague J., et al. Menopause. 2018 Aug;25(8):862-869 Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo % change from baseline Hot flash frequency Hot flash severity Placebo MLE4901 Hot flash bother Hot flash interference Fig.2.
Slide 37: Osanetant: Clinical Development Plan
Acer is partnering with leading universities to design & conduct a clinical trial to evaluate osanetant in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women who are BRCA+ and have had a PBSO Men with HR+ Prost
Slide 38: Osanetant: Exclusivity / Timelines
Osanetant would be a New Chemical Entity (NCE) in the US, and as such would be eligible for five years’ market exclusivity from potential FDA approval Additional exclusivity (e.g. Orphan Drug Designation) will depend upon indication(s) and development pathway chosen Anticipate IND submission in Q4 2
Slide 39: Financial Overview
Cash $12.1M as of December 31, 2019 Expected to have sufficient capital into Q4 2020, excluding support for the planned emetine trial and EDSIVO™ development and precommercial activities Capitalization as of April 30, 2020 10.2M shares of common stock outstanding 11.6M shares of common stock fully d
Slide 40: Summary
Summary ACER Acer’s pipeline includes four clinical-stage product candidates: Emetine for the treatment of COVID-19 EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a taste-masked, immediate re
Slide 41: Reference Slides
acertherapeutics Reference Slides
Slide 42: Maple Syrup Urine Disease (MSUD)
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 43: ACER-001 MSUD: Clinical POC
ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at BCM – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Results: NaPB demonstrated stati
Slide 44: MSUD: Market Opportunity
About 1,000 MSUD patients in the U.S., ~3,000 WW* 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD Early treatment may help reduce the rate of neuropsychological comorbidities and optimize g